NASDAQ:LBPH • US54300N1037
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for Longboard Pharmaceuticals Inc (LBPH).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2024-10-15 | Truist Securities | Downgrade | Buy -> Hold |
| 2024-10-15 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2024-10-14 | Cantor Fitzgerald | Downgrade | Overweight -> Neutral |
| 2024-10-14 | B. Riley Securities | Downgrade | Buy -> Neutral |
| 2024-09-18 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-09-17 | Wedbush | Maintains | Outperform -> Outperform |
| 2024-09-16 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-09-10 | Truist Securities | Initiate | Buy |
| 2024-08-26 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2024-08-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-05 | B. Riley Securities | Maintains | Buy -> Buy |
| 2024-08-02 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-08-02 | Wedbush | Maintains | Outperform -> Outperform |
| 2024-08-02 | Citigroup | Maintains | Buy -> Buy |
| 2024-08-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-11 | Baird | Maintains | Outperform -> Outperform |
| 2024-07-02 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2024-07-02 | Citigroup | Maintains | Buy -> Buy |
| 2024-06-20 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-06-20 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2024-06-11 | B. Riley Securities | Maintains | Buy -> Buy |
| 2024-06-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-03 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-05-03 | Wedbush | Maintains | Outperform -> Outperform |
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A 3,203.35% | N/A 299.40% | N/A 94.41% | N/A 41.12% | N/A 89.00% | |||||
| EBITDA YoY % growth | N/A | -27.84M | -44.79M -60.88% | -56.754M -26.71% | N/A -69.66% | N/A -35.91% | N/A -20.65% | N/A 60.14% | N/A 169.21% | N/A 396.72% | N/A | N/A | |
| EBIT YoY % growth | -14.4M | -27.84M -93.33% | -44.8M -60.92% | -56.759M -26.69% | N/A -75.49% | N/A -31.79% | N/A -19.69% | N/A 12.75% | N/A 90.92% | N/A 1,273.61% | N/A 80.67% | N/A 87.89% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | -2.15 | -2.57 -19.53% | -2.38 7.39% | N/A 4.61% | N/A -26.89% | N/A -11.47% | N/A -8.21% | N/A 41.78% | N/A 93.78% | N/A 1,789.62% | N/A 278.73% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.64 -3.17% | -0.70 -65.63% | -0.72 -28.96% | -0.72 -14.30% | -0.74 -15.44% |
| Revenue Q2Q % growth | |||||
| EBITDA Q2Q % growth | -26.826M -72.32% | -20.263M -11.90% | N/A | N/A | N/A |
| EBIT Q2Q % growth | -28.412M -82.44% | -31.722M -75.16% | -33.316M -29.92% | -34.655M -23.22% | -37.243M -31.08% |
All data in USD
13 analysts have analysed LBPH and the average price target is 65.96 USD. This implies a price increase of 9.97% is expected in the next year compared to the current price of 59.98.
The consensus EPS estimate for the next earnings of Longboard Pharmaceuticals Inc (LBPH) is -0.64 USD and the consensus revenue estimate is 0 USD.
The number of analysts covering Longboard Pharmaceuticals Inc (LBPH) is 13.